Switch to:

Key Ratios

New Key Statistics Module, Z-Score and F-Score
Market Cap $M79.8Revenue (TTM) $M29.5Net Margin (%)-128.8Altman Z-Score-6.2
Enterprise Value $M149EPS (TTM) $-0.8Operating Margin %-109.4Piotroski F-Score3
P/E(ttm)--Beneish M-Score-2.4Pre-tax Margin (%)-128.6Higher ROA y-yN
Price/Book--10-y EBITDA Growth Rate %--Quick Ratio6.5Cash flow > EarningsY
Price/Sales2.05-y EBITDA Growth Rate %0.5Current Ratio6.6Lower Leverage y-yN
Price/Free Cash Flow--y-y EBITDA Growth Rate %--ROA % (ttm)-55.0Higher Current Ratio y-yN
Dividend Yield %--PEG--ROE % (ttm)-160.3Less Shares Outstanding y-yN
Payout Ratio %--Shares Outstanding M64.9ROIC % (ttm)-112.2Gross Margin Increase y-yY

Gurus Latest Trades with ALIM

Number of guru portfolios checked: 68.
Ticker Guru Date Action
Impact Price Range
(Average)*
Current Price Change from Average Comment Current Shares

ALIM is held by these investors:



ALIM: Insider Buys/Sells

Click Here for All Insider Trades.
InsiderPosition Date Trades Shares Trade Price ($) Change (%) Details
Roberts Calvin W.Director 2016-12-12Sell50,000$1.1110.81view
EISWIRTH RICHARD S JRPresident and CFO 2016-09-15Sell51,471$1.51-18.54view
BAVP, L.P.10% Owner 2016-04-21Sell478,673$2.59-52.51view
EISWIRTH RICHARD S JRCOO and CFO 2015-12-16Sell46,669$2.31-46.75view
Flynn James E 2015-12-08Buy272,249$3.01-59.14view
Flynn James E 2015-12-03Buy243,252$3-59view
Flynn James E 2015-11-06Buy73,250$2.98-58.72view
Flynn James E 2015-10-30Buy16,542$3-59view
Flynn James E 2015-10-28Buy59,342$3-59view
Flynn James E 2015-10-26Buy60,364$3-59view

Quarterly/Annual Reports about ALIM:

    News about ALIM:

    Articles On GuruFocus.com
    Alimera Sciences Inc. (ALIM) President and CEO C. Daniel Myers sells 45,523 Shares Mar 16 2011 
    The Most Speculative Stocks on the Market: Harbinger, Kaching Kaching, Alimera Sciences, Star Scient Jul 29 2010 

    More From Other Websites
    Alimera Sciences to Report Fourth Quarter 2016 Financial Results on March 1, 2017 Feb 23 2017
    8:05 am Alimera Sciences and Knight Therapeutics announce that Knight's New Drug Submission for... Feb 22 2017
    Alimera Sciences and Knight Therapeutics Announce Filing of New Drug Submission for Iluvien® in... Feb 22 2017
    Alimera Sciences and Knight Therapeutics Announce Filing of New Drug Submission for Iluvien(R) in... Feb 22 2017
    Alimera Sciences Announces the Reimbursement of ILUVIEN® in Italy Feb 06 2017
    ETFs with exposure to Alimera Sciences, Inc. : January 11, 2017 Jan 11 2017
    Is Alimera Sciences Inc (ALIM) A Good Stock To Buy? Dec 18 2016
    ETFs with exposure to Alimera Sciences, Inc. : December 16, 2016 Dec 16 2016
    ETFs with exposure to Alimera Sciences, Inc. : December 6, 2016 Dec 06 2016
    ALIMERA SCIENCES INC Files SEC form 8-K, Submission of Matters to a Vote of Security Holders Nov 16 2016
    ETFs with exposure to Alimera Sciences, Inc. : November 14, 2016 Nov 14 2016
    ALIMERA SCIENCES INC Financials Nov 11 2016
    ALIMERA SCIENCES INC Files SEC form 10-Q, Quarterly Report Nov 04 2016
    Alimera Sciences, Inc. :ALIM-US: Earnings Analysis: Q3, 2016 By the Numbers : November 4, 2016 Nov 04 2016
    Edited Transcript of ALIM earnings conference call or presentation 3-Nov-16 2:00pm GMT Nov 03 2016
    ETF’s with exposure to Alimera Sciences, Inc. : November 3, 2016 Nov 03 2016
    ALIMERA SCIENCES INC Files SEC form 8-K, Results of Operations and Financial Condition Nov 03 2016
    Alimera Sciences Announces Third Quarter 2016 Financial Results and Provides Business Update Nov 02 2016
    Alimera Sciences Begins Selling ILUVIEN® in the Middle East Oct 26 2016
    Alimera Sciences to Report Third Quarter 2016 Financial Results on November 2, 2016 Oct 25 2016

    Add Notes, Comments

    If you want to ask a question or report a bug, please create a support ticket.
    Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
    GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)